Tuesday, February 10, 2026 at 11:33 AM
AstraZeneca is forecasting steady profit growth and is confident in reaching its ambitious goal of $80 billion in annual sales by 2030, driven by new medicines and investments, despite challenges from US policies.
The bank is projecting higher revenue and lower costs, after reporting a stronger net profit for the fourth quarter.
The pharma major said it faces the largest drug-patent expiry headwind in its history this year.
The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.
Cigna Group logged higher revenue in its latest quarter as its pharmacy-benefit business Evernorth continues to grow.
